[The influence of hormone replacement therapy containing transdermal 17-beta estradiol and oral medroxyprogesterone acetate on coagulation and fibrinolysis].
OBJECTIVE
The aim of the study was to evaluate some coagulative and fibrinolytic changes in women taking hormone replacement therapy (HRT).


METHODS
In 29 women aged 45-64 years with osteoporosis and climacteric symptoms several fibrinolytic and coagulative parameters were measured. These measurements were performed three times in each women--before and after three and six months of HRT containing transdermal 17 beta-estradiol (50 mg per day) and oral medroxyprogesterone acetate (2.5 mg per day).


RESULTS
PAI-1 (antigen) and factor VII (activity) were decreased significantly during the trial. No other significant modifications in the examined parameters (fibrinogen, antithrombin III, protein C, protein S, thrombin-antithormbin III complexes, t-PA and D-dimers) were detected.


CONCLUSIONS
The hormone replacement therapy can reduce the risk of coronary heart disease thanks to decreased levels of PAI-1 and factor VII. No other changes in coagulation and fibrinolysis were observed during the treatment.
Stachowiak
G
G
Kliniki Chorób Menopauzy ICZMP w Lodzi.
Owczarek
D
D
Połać
I
I
Pertyński
T
T
Jedrzejczyk
S
S
D000279:Administration, Cutaneous; D000284:Administration, Oral; D001777:Blood Coagulation / Q000187:drug effects*; D004958:Estradiol / Q000494:pharmacology*; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects; D020249:Hormone Replacement Therapy / Q000379:methods*; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000494:pharmacology*; D008875:Middle Aged; D045167:Progesterone Congeners / Q000494:pharmacology*
D045167:Progesterone Congeners; D004958:Estradiol; D017258:Medroxyprogesterone Acetate